Transplant man meets donor’s sister


A woman, whose brother was killed in a traffic accident, has met the man who was given his face in a pioneering transplant operation.

Footage from Channel 9’s 60 Minutes programme in Australia shows the moment Rebekah Aversano sees – and touches – the face of her dead brother.

The recipient, Richard Norris, from Virginia, US, was severely injured in a shotgun accident 15 years ago.

Until the operation he had rarely gone outside and lived as a recluse.

‘Tragic loss’

Transplant recipients do not normally meet the families of their donors.

But Ms Aversano, from Maryland, came face to face with the man who received some of her brother’s facial tissues and structures.

She touched his face and said: “This is the face I grew up with.”

Her brother, Joshua Aversano, had been killed in a road traffic accident, at the age of 21.

The decision to donate his face had been difficult, but would have been what he wanted, said his mother Gwen Aversano in a separate interview with CTV News.

She said: “Knowing our son he would have wanted someone else to go on with their lives if he wasn’t able to.

“After meeting Mr Norris, seeing him and speaking to him we can definitely see our son in him.

“We were just so pleased we were able to help Mr Norris even though we had such a tragic loss,” she added.

The extensive transplant surgery took place at the University of Maryland three years ago. It lasted more than 36 hours.

Mr Norris had lost his lips and nose in a shotgun accident and had limited movement of his mouth.

Richard Norris before his face transplant operation (Photo: University of Maryland Medical Center)
Richard Norris lived as a recluse for 15 years after losing his nose, lips and teeth in a gun accident.

James Partridge, founder of the charity Changing Faces which supports people with facial disfigurements, told the BBC he did not know of another case where the family of the donor had met the person who had received the face.

And Mr Barry Jones, former president of the British Association of Aesthetic Plastic Surgeons, said there were many issues to consider.

“It must be rather difficult for any relative to meet a recipient but it must be particularly difficult for faces,” he told the BBC.

“On this occasion it seems to have been a happy outcome. But that might not always be the case.”

Mr Jones said a family would have to ponder how they would feel about the personality of the person with the new face.

“I am not against recipients meeting donor families if both parties want too, but I hope they have been counselled properly before their meeting,” he said.

Laser Weapons Get Real


Silently, the drone aircraft glides above the arid terrain of New Mexico—until it suddenly pivots out of control and plummets to the ground.

Then a mortar round rises from its launcher, arcs high and begins to descend towards its target—only to flare and explode in mid-flight.

On the desert floor, on top of a big, sand-coloured truck, a cubic mechanism pivots and fires an invisible infrared beam to zap one target after another. This High Energy Laser Mobile Demonstrator (HEL MD) is a prototype laser weapon developed for the US Army by aerospace giant Boeing of Chicago, Illinois. Inside the truck, Boeing electrophysics engineer Stephanie Blount stares at the targets on her laptop’s screen and directs the laser using a handheld game controller. “It has a very game-like feel,” she says.

That seems only natural: laser weapons are a staple of modern video games, and ray-guns of various sorts were common in science fiction for decades before the first real-life laser was demonstrated in 1960. But they are not a fantasy anymore. The Boeing prototype is just one of several such weapons developed in recent years in both the United States and Europe, largely thanks to the advent of relatively cheap, portable and robust lasers that generate their beams using optical fibers.

The output of these fiber weapons is measured in kilowatts (kW), orders of magnitude less than the megawatt-class devices once envisioned for the US Strategic Defense Initiative—an ultimately unsuccessful cold-war plan that sought to use lasers to disable ballistic missiles carrying nuclear warheads.

But the modern, less ambitious, weapons are on the brink of real-world deployment. Tests such as those of the Boeing system show that the lasers have enough power to overcome threats from terror groups—at a fraction of the price of conventional defences. “It’s a very cost-effective solution to taking out cheaply made weapons like small mortars or rockets made out of sewer pipe,” says Blount.

In late 2014, for example, the US Navy showed that a ship-mounted laser-weapon system called LaWS could target small boats, such as those used by terrorists and pirates. That experimental weapon is currently installed on the USS Ponce, an amphibious support ship in the Gulf.

Many challenges to full-scale deployment remain, warn developers, from the need to boost the weapons’ power to the difficulty of operating a laser in fog and clouds. But specialists in defence and security are starting to take lasers seriously. “After a nearly half-century quest, the US military today is on the cusp of finally fielding operationally relevant directed-energy weapons,” wrote Paul Scharre, an advanced-technology specialist at the Washington DC-based Center for a New American Security (CNAS), in report on laser weapons released in April.

The power predicament
Laser weapons have long fascinated weapons developers—most notably during the heyday of the Strategic Defense Initiative, nicknamed Star Wars, in the 1980s and 1990s. US spending on laser-weapons research peaked in 1989 when, according to the CNAS report, the government spent the equivalent of US$2.4 billion in 2014 dollars. Funding has continued at lower levels ever since. Yet the original goal, of being able to shoot down incoming ballistic missiles, proved unattainable.

The trick with any laser weapon is to focus its energy into a spot that is small enough to heat up and damage the target—and to do that with a machine that is compact and portable enough for the battlefield. This is easier said than done. In 1996, for example, the US Air Force initiated the Airborne Laser project as one of its contributions to defence against ballistic missiles. Because it was impossible at the time to generate the required megawatts of optical power electrically, the developers chose a chemical oxygen iodine laser (COIL) that could be fuelled by a chemical reaction. But the COIL was so bulky that it could only be carried on a Boeing 747, and left little space for laser fuel. “It needed remote mixing units and chemicals weighing tens of thousands of pounds,” says Paul Shattuck, head of directed-energy systems for Lockheed Martin Space Systems, which provided the project’s beam-control technology.

Another major problem was the atmosphere, says Phillip Sprangle, senior scientist for directed-energy physics at the Naval Research Laboratory in Washington DC. Not only was the beam scattered by dust and natural turbulence, he says, but its passage caused ‘thermal blooming’. When the beam propagated at very high powers, Sprangle explains, “the atmosphere absorbed laser light, heating the air and causing the laser beam to spread out”. That spreading, in turn, dissipated the laser’s energy.

The good news for the Airborne Laser project was that this issue, at least, had a solution: adaptive optics technology similar to that used by astronomers to clarify their view of the stars (see Nature517, 430–432; 2015). The technology uses mirrors to automatically distort the laser beam in a way that cancels the effects of the turbulence, with the same result as a pair of glasses correcting for aberrations in the eye. “As the laser beam passes through the atmosphere,” says Shattuck, “it cleans up, and it’s nice and tight when it gets to the target.”

By 2010, the adaptive optics was good enough for the Airborne Laser to destroy a ballistic missile in flight. By then, however, logistical issues such as the size problem had led the Department of Defense to lose its enthusiasm for energy weapons in general. It cancelled the Airborne Laser programme outright by early 2012. At the same time, the department’s spending on high-energy lasers in general was falling; it dropped from $961 million in 2007 to $344 million in 2014.

Fibers in the spotlight
The money did not vanish entirely: attention was already shifting to fiber lasers as a way to deliver results more economically. Fiber lasers were invented in 1963, and since the 1990s they have been advanced almost entirely by IPG Photonics in Oxford, Massachusetts. Whereas other solid-state lasers use rigid rods, slabs or discs of crystal to generate the beam, and so have to be fairly large, fiber lasers use thin optical fibers that can be wrapped into compact coils (see ‘Fiber power’). The fibers can collect their optical energy from brighter versions of the cheap laser diodes used in DVD players, and then amplify the light to higher power, with overall electrical-to-optical conversion efficiencies greater than 30%. This is at least double the efficiency typical of other solid-state lasers, and close to that of chemical lasers such as COIL. And, being intrinsically long and thin, the fibers have a high surface area to volume ratio and can radiate away waste heat very quickly—an ability that helps to give the lasers a long working life and low maintenance requirements.

These advantages first attracted attention during the 1990s, when fiber lasers began to be used to beef up optical signals carrying Internet data through undersea cables. But since the early 2000s, IPG has focused on developing kilowatt-class industrial lasers for welding, drilling and cutting—devices that also attracted the attention of military researchers.

Around 2010, recalls Shattuck, he and his colleagues at Lockheed Martin heard from Israeli civilians targeted by rockets launched from the Gaza Strip. “The mayor of a village stood up and said, ‘Please, give me some kind of defence,’” Shattuck says. This inspired Lockheed Martin to develop the Area Defense Anti-Munitions (ADAM) system, which uses an off-the-shelf 10-kW laser from IPG to keep costs down. Since 2012, the company has shown that ADAM can disable targets such as boats, drones and simulated small-calibre rockets from about 1.5 kilometres away. Although unwilling to disclose the price of ADAM—or whether anybody has bought one—Lockheed Martin says that it is now ready to provide the system to customers.

Blount is less reticent about Boeing’s HEL MD prototype, which also uses a commercial 10-kW fiber laser. With the system drawing its power from the vehicle engine or a separate generator, she says, “it takes less than two cups of fuel to fire the laser for long enough to disable many targets.” This makes it much cheaper to use for defence than conventional missiles. “An inexpensive missile is $100,000 and that’s one shot,” says David DeYoung, Boeing’s director of directed-energy systems. “To shoot a laser-weapon system once is less than $10.”

Blount stresses that the resurgence of laser weapons owes at least as much to advanced image-recognition and targeting systems as to the laser itself. “The better the pointing and tracking system,” she says, “the better able you are to put the beam on the most vulnerable point of a target.”

Thanks to computerized aiming, HEL MD can operate in wholly autonomous mode, which Boeing tested successfully in May 2014—although the trials uncovered an unexpected challenge. The weapon’s laser beam is silent and invisible, and not all targets explode as they are destroyed, so an automated battle can be over before operators have noticed anything. “The engagements happen quickly, and unless you’re staring at a screen 24–7 you’ll never see them,” Blount says. “So we’ve built sound in for whenever we fire the laser. We plan on taking advantage of lots of Star Trek and Star Wars sound bites.”

Strength in numbers
Aiming and targeting may be battle-ready, but power is still a problem. A commercial laser’s 10-kW output is at the low end of what is useful for laser weapons. And using fibers puts limits on the beam’s power and quality—not least because at high powers, the cascade of photons surging through the fiber can heat it up faster than it can radiate the energy, and can thus cause damage. To avoid this, researchers are working to combine the output from several lasers.

The ideal way to do this would be ‘coherent combining’, in which the waves from each laser march together in tightly synchronized formation. This technique is widely used in radio and microwave applications, says Tso Yee Fan, a laser scientist at the Massachusetts Institute of Technology’s defence-oriented Lincoln Laboratory in Lexington. But coherence is much tougher to achieve with visible and infrared light. The waves from each laser must have almost identical wavelengths, the planes of their oscillations must precisely align, and the peaks and troughs of each wave must coincide. “In radio-frequency or microwaves, the wavelength’s a few centimetres,” Fan says. “In optics, the wavelength’s around a micrometre, so being able to do those kinds of controls has been really difficult.”

But that may not matter much, says Sprangle. In 2006, he and his team reported computer simulations suggesting that an ‘incoherent combination’ of several fiber-laser beams hitting a single spot would be almost as effective as a coherent combination. With either approach, he says, “when you’re propagating over long ranges through atmospheric turbulence, you get approximately the same power on the target”. In 2009, his group confirmed this theory by using mirrors to combine 4 fiber-laser beams into a 5-centimetre spot on a target more than 3 kilometres away.

Building on Sprangle’s work, the US Office of Naval Research has developed the 30-kW LaWS, which incoherently combines six commercial fiber-lasers. LaWS has been installed on the USS Ponce since September 2014, and has been tested on objects such as small boats and drones.

The missile-specialist MBDA Germany in Schrobenhausen has developed a similar approach. In October 2012, the firm successfully used its 40-kW combined fiber-beam system to destroy model artillery shells towed through the air some 2 kilometres away. MBDA’s tests have also helped to debunk the science-fiction idea that reflective armour would defend against laser weapons. They found that any dust on the mirrored surface would get burned in, and lead to the destruction of the target even faster than with a non-reflective surface.

Markus Martinstetter from MBDA’s Future Systems Directorate argues that high-precision targeting minimizes the chances of accidentally hurting bystanders while trying to shoot down targets, especially compared with conventional explosives. “There is no risk from fragmenting ammunition and we only start the irradiation when the aim point is exactly on target,” he says.

Lockheed Martin is also working on laser weapons that can take on targets that are more complex or farther away than can be tackled by its low-cost ADAM system. In March, for example, the company reported that its Advanced Test High Energy Asset (ATHENA) system could disable the running engine of a small truck mounted on a test platform. ATHENA uses a similar adaptive-optics system to the Airborne Laser, coupled with Lockheed’s Accelerated Laser Demonstration Initiative (ALADIN) fiber-laser system.

ALADIN combines the output of several fiber lasers, each with a slightly different wavelength, into a single 30-kW beam. This ‘wavelength beam combining’ approach originated at the Lincoln Laboratory and is similar to methods that channel Internet traffic into fiber-optic cables. Fan notes that this method is easier than coherent combining, but gives better-quality beams than incoherent combining, so it can more easily hit smaller targets from longer distances.

Jason Ellis, a visiting fellow at the CNAS and lead author of the think tank’s laser-weapons report, says that such developments convince him that fiber-laser weapons are coming of age—and that emerging advances could take them to hundreds of kilowatts and extend their range to hundreds of kilometres.

Despite such advances, a February 2014 poll of US national-security specialists found that just one-fifth believed that directed-energy weapon technologies would be mature within a decade.

Michael Carter, a programme manager for photon science at Lawrence Livermore National Laboratory in Livermore, California, cautions that today’s lasers are a very long way from their science-fiction counterparts. “They’re not yet the Star Trek phaser,” he says. “People talk about speed-of-light engagement, but it still takes time to demolish targets. At the most basic level, if you can’t see it—if there’s too much rain or fog—your laser can’t hit it.” He suggests that the greatest value of the current generation of demonstration systems may be in working out how to handle such broader challenges before better lasers emerge. “Don’t mistake what they’re doing on the USS Ponce for a new strategic superiority,” Carter warns. “It may be the first step in that direction but it’s not going to change the game by itself.”

Even the weapons companies are cautious not to overstate their case. For example, MBDA expects that it will take 3–5 years for truly operational systems to appear even in the tens of kilowatts range. And in some circumstances—such as a foggy day—conventional weapons will always be more effective. “You give the defender of the future both, and put the choice in their hands,” DeYoung recommends.

Despite their modest capabilities, Scharre claims that fiber-laser weapons could find a niche in US military defence in 5–10 years. “They may not be as grand and strategic as the Star Wars concept,” he says, “but they could save lives, protect US bases, ships and service members.”

Check typhoid to control gallbladder carcinoma


By controlling bacterial infection causing typhoid fever could dramatically reduce the risk of gallbladder cancer in India and Pakistan. A study conducted by researchers of the Institute of Medical Sciences, Banaras Hindu University (BHU) and the Netherland Cancer Institute, was published in CELL HOST & Microbe journal on Thursday. The study was done by Gopal Nath of the department of Microbiology, Institute of Medical Sciences, and Jacques and Neefjes Tiziana Scanu of Netherlands Cancer Institute.

According to Nath, the findings establish for the first time the causal link between bacterial infection and gall bladder cancer, explaining why this type of cancer is rare in the West but common in Indian subcontinent where typhoid fever is endemic. Public policy changes inspired by this research could have an immediate impact on preventing a type of cancer that currently has a very poor prognosis. While viruses are among the established causal factors for particular cancers, bacteria are largely ignored as direct contributors. Accepting that bacterial infections can directly contribute to cancer formation makes these tumors preventable in principle. If Salmonella Typhi infections are cured immediately antibiotics and chronic infection are prevented or cured by some means or if vaccination programme to eradicate S. Typhi work, a major reduction is expected in the incidence of a tumor that represents the third commonest gastrointestinal tumor in India and Pakistan.

Gall bladder cancer is hard to diagnose in its early stages because there are no signs or symptoms. By the time cancer is detected, it is often too late to save the patients. Professor VK Shukla, a gastrointestinal surgeon, said that usual survival period of such patients hardly exceeds 6 months after the detection. Because the prognosis is so poor, the researchers set out to gain insight into how to combat this tumor by identifying causal factors underlying its unique global distribution. They zeroed in on S. Typhi because this — causing bacterium is endemic in India and have been associated with gallbladder cancer in many of epidemiological studies including one which was published by Gopal Nath and his research group in 2008. Moreover, proteins that Salmonella injects into host cells activate cancer related signaling pathways called AKT and MAPK, which support not only bacterial infection and survival but also the growth and proliferation of cancer cells.

According to them, to explore the role of S. Typhi in cancer in the new study, Neefjes and Scanu compared tumor samples from Indian and Dutch patients with gall bladder cancer. While both group showed signs of AKT and MAPK activation and an inactive TP53 cancer gene, only Indian patients showed strong evidence of S. Typhi infection and over activating mutation in cancer gene c-Myc. To mimic the features of tumor samples from India, the researchers transplanted Salmonella- infected cells with mutations affecting TP53 and c- Myc activity in mice. These mice latter developed tumors, demonstrating that Salmonella causes cancer in genetically at-risk host as a result of the collateral damage induced by its normal infection cycle.

Additional experiments suggested that Salmonella infection sets genetically predisposed host cells on the cancerous path by secreting proteins that increase AKT and MAPK activity, which remains elevated and perpetuates the cancer trajectory long after the bacteria have disappeared. These same two host signaling pathways are activated by bacterial pathogens implicated in cervical and lung cancer, suggesting that a direct contribution of bacteria to tumor formation could be more common than previously anticipated. The findings also suggest that the use of antibiotic treatment to control these bacterial infections may come too late for individuals who have already developed cancer. Instead, the main goal should be prevention through proper treatment with different antibacterial modalities, vaccination program and better sanitary conditions.

In future studies, the researcher will investigate whether Salmonella contributes to tumors in other tissues, identify other cancer causing bacteria, and determine how these pathogens leave an imprint of infection in host cells. “Our findings may now be used to urge policy makers to take appropriate measures to eliminate or better control these infections,” Dr Nath says adding, “If typhoid fever is controlled, gallbladder carcinoma in Indian subcontinent could be prevented and become as rare as in the Western world”.

Medical journals serve as Big Pharma drug-marketing platform.


The value of medical journals in providing physicians, researchers and other medical professionals an honest glimpse of the latest relevant, peer-reviewed medical science has greatly diminished in recent years. An extensive review published in the journal PLOS Medicine shows that medical journals today serve as little more than marketing platforms for pharmaceutical companies to push their drugs with little in the way of unbiased science.

Richard Smith, who served as an editor of the prestigious British Medical Journal (BMJ) for 25 years before resigning in 2004, warns that a bulk of the studies published in medical journals are pioneered by drug companies. More often than not, these studies push the agenda of the companies that launched them, procuring positive results that were cunningly derived through industry sleight of hand.

We’re not talking about pharmaceutical advertising here, which is also highly endemic in terms of conflicts of interest. We’re talking about studies — mainly randomized clinical trials — launched by drug companies that arrive at predetermined outcomes and are widely perpetuated in the medical literature to create the illusion that drugs and vaccines are safe and effective.

“Journals have devolved into information laundering operations for the pharmaceutical industry,” wrote Richard Horton, editor of The Lancet journal, back in March 2004, just one year before Smith published the review in question.

It’s not so much drug advertising as it is sponsored trials that corrupt medical journals

Although pharmaceutical advertising renders the quality of what’s been published in a given medical journal questionable, at least readers of that journal can see these advertisements and determine how seriously to take the contained studies. However, when the studies themselves are industry-sponsored and this is not disclosed, things get messy.

“A large trial published in a major journal has the journal’s stamp of approval (unlike the advertising), will be distributed around the world, and may well receive global media coverage, particularly if promoted simultaneously by press releases from both the journal and the expensive public-relations firm hired by the pharmaceutical company that sponsored the trial,” writes Smith.

“For a drug company, a favourable trial is worth thousands of pages of advertising, which is why a company will sometimes spend upwards of a million dollars on reprints of the trial for worldwide distribution. The doctors receiving the reprints may not read them, but they will be impressed by the name of the journal from which they come. The quality of the journal will bless the quality of the drug.”

Up to 75% of clinical trials published in major journals like JAMA, Lancet, NEJM, and Annals of Internal Medicine are industry-sponsored

Then there’s the issue of what’s actually being published in many of the world’s most well-respected medical journals. Upon investigation, Smith found that upwards of 75 percent of what is being published today in journals like Annals of Internal Medicine, the Journal of the American Medical Association (JAMA), The Lancet and the New England Journal of Medicine (NEJM) are trials that have been directly funded by industry.

Smith’s systematic review uncovered that drug companies have become very adept at reaching the conclusions they desire by manipulating randomized trials. This is not necessarily accomplished through direct fraud (although that happens as well), but instead it occurs by engaging in what Smith says is “asking the ‘right’ questions.”

“The companies seem to get the results they want not by fiddling the results, which would be far too crude and possibly detectable by peer review, but rather by asking the ‘right’ questions,” Smith writes.

These include:

• Conducting a trial of a given drug against a treatment known to be inferior
• Conducting a trial against too low of a dose of a competitor drug
• Conducting a trial against too high of a dose of a competitor drug, making the drug in question seem less toxic
• Conducting a trial that is too small to show differences from competitor drugs
• Using multiple endpoints in a trial and selecting for publication only those that provide favorable results
• Conducting multi-center trials and selecting for publication only those that reach favorable results
• Conducting subgroup analyses and selecting for publication only those that are favorable
• Presenting results that are most likely to impress, such as showing a reduction in relative as opposed to absolute risk

New Marijuana Breathalyzers Currently Being Tested


While many parts of the country are working on legalization laws that would allow the use of medical marijuana by anyone with a prescription, private companies and local law enforcement agencies aren’t far behind. Multiple groups are working on marijuana or weed breathalyzers that would allows police officers to crack down on drug-related DUIs.

Drug Use Behind the Wheel Increases

According to two new studies on impaired driving by the National Highway Traffic Safety Administration (NHTSA), drunk driving is declining, while drugged driving is on the rise. One of those studies discovered that the total number of drivers with alcohol in their system has diminished by nearly 33 percent since 2007 (and almost 75 percent since the first survey in 1973). On the other hand, there has been a significant uptick in the amount of drivers using marijuana and other illegal drugs. Nearly 25 percent of surveyed drivers tested positive for at least one illegal drug that could impair driving skills or affect road safety.

A second study found that marijuana users are more likely to be involved in car accidents than alcohol-influenced counterparts. However, the researchers admit that this increase could be caused by the fact that marijuana users are more apt to travel in groups and are predominantly men (both high risk factors). “Drivers should never get behind the wheel impaired, and we know that marijuana impairs judgment, reaction times and awareness,” concluded Jeff Michaels, the administrator behind the study.

New Breathalyzers in Testing Phases

As things currently stand, a driver typically has to agree to give blood samples in order for law enforcement to determine whether the motorist is under the influence of marijuana. The game could soon be changing, though.

Researchers for Washington State were the first to make headlines in January when they revealed that they had begun working on a breath test that would detect marijuana in drivers. Their aim is to help police officers quickly identify when someone is driving under the influence, much like an alcohol detection device.

Another device, cleverly nicknamed The Cannibuster, is also in testing phases. The two biomedical engineering students behind the prototype, Kathleen Stitzlein and Mariam Crow, say the device uses lab-on-chip technology and noninvasive saliva testing to quickly detect THC levels.

“Today, if a driver is suspected of impaired driving due to marijuana, law enforcement officers must call an Emergency Medical Squad to the scene or take the driver to a local hospital for blood work,” said Stitzlein. She further mentioned that lab results could take as long as six weeks to come back, which is anything but ideal in a legal situation.

However, the race for superior technology doesn’t stop there. Plenty of other companies, including Cannabix Technologies, are working hard to win the race. Founded by a former Canadian Mounted Policeman, Cannabix Technologies’ device doesn’t measure the amount of THC in the body, butsimply gives a reading of whether or not any THC is present in the body. Preliminary research suggest positive results occurs within the first two hours of marijuana use, which correlates pretty well with the duration and time of impairment.

 

image

What Marijuana Breathalyzers Would Mean

While we’re still a ways away from any THC breathalyzer technology finding its way into a police cruiser, there are no shortages of opinions. Many support it, citing the NHTAs newest studies as proof that driving while drugged is more dangerous than driving while drunk. However, others firmly warn against premature adoption.

Criminal defense attorney Adam Banner believes it could “do more harm than good,” by producing inaccurate readings and further complicating a legal system that’s already filled to the brim with cases and appeals. Only time will tell, but this will certainly be an interesting issue to keep an eye on.

Researchers develop an iris scanner that can work at 12 metres away – ScienceAlert


Imagine an advertising billboard or a smart door that can recognise you from across the street – that’s the futuristic type of technology that’s on the way after researchers the US developed an iris scanner that can work at a distance of 12 metres (40 feet).

We’re starting to see primitive eye scanners appear in consumer electronics, but this new device takes the innovation one step further. The team from Carnegie Mellon University (CMU) has developed a scanning system that can spot and identify a driver sat in a car, so whether you’re traveling through a toll bridge or exceeding the speed limit, the cameras will know who you are.

That brings up a whole series of difficult questions about user privacy and the capabilities of law enforcement agencies across the world. Given a positive spin, it means a dangerous criminal getting spotted ahead of time; seen more cynically, the technology could be used to track citizens without their knowledge.

This long-range iris scanning system is primarily the work of CMU engineering professor, Marios Savvides. As our irises are as distinctive as our fingerprints, the technology is very accurate – but as with fingerprints, your eyeballs will already need to be on file for you to be spotted.

Savvides thinks the technology is helpful rather than scary. “Fingerprints, they require you to touch something. Iris, we can capture it at a distance, so we’re making the whole user experience much less intrusive, much more comfortable,” he told The Atlantic. “There’s no X-marks-the-spot. There’s no place you have to stand. Anywhere between six and 12 metres, it will find you, it will zoom in and capture both irises and full face.”

If nothing else, it could speed up queues at the airport. But in the wrong hands or used in the wrong way, it could be just as dangerous as it is convenient. There’s no chance of these types of biometric technology going backwards, so rigorous laws on how it can be used become increasingly important.

Savvides thinks we’re already in a new era of surveillance, and that his invention won’t change that. “People are being tracked,” he says. “Their every move, their purchasing, their habits, where they are every day, through credit card transactions, through advantage cards – if someone really wanted to know what you were doing every moment of the day, they don’t need facial recognition or iris recognition to do that. That’s already out there.”

Like many recent advancements in biometrics, increased convenience and accuracy comes at a cost – it’s all a question of how the technology is used. Just don’t be surprised if in the near future your office door spots you well before you reach it.

FDA Approves Treatments for Irritable Bowel Syndrome with Diarrhea


The FDA today approved eluxadoline (Viberzi) and rifaximin (Xifaxan) to treat irritable bowel syndrome with diarrhea (IBS-D). Viberzi can be taken twice daily with food, while Xifaxan can be taken orally 3 times a day for 2 weeks to treat abdominal pain and diarrhea. In addition, if patients experience a recurrence of symptoms, they can retake Xifaxan over a 2-week period up to 2 times. Trials involving 2425 patients taking Viberzi or placebo demonstrated that the treatment was more effective than placebo in reducing abdominal pain and improving stool consistency over a 26-week treatment period. Xifaxan’s efficacy was shown in 3 trials. The first 2 trials involved 1258 patients who were randomly assigned to take Xifaxan or placebo for 2 weeks, followed by a 10-week period with no treatment. The researchers found that patients taking Xifaxan saw improvements in abdominal pain and stool consistency compared with those on placebo. The third trial with 636 subjects demonstrated that patients saw improvements on Xifaxan, even through repeat rounds of the treatment with some periods off treatment. “For some people, IBS can be quite disabling, and no 1 medication works for all patients suffering from this gastrointestinal disorder,” Julie Beitz, MD, director of the Office of Drug Evaluation III in FDA’s Center for Drug Evaluation and Research, said in a press release. “The approval of 2 new therapies underscores the FDA’s commitment to providing additional treatment options for IBS patients and their doctors.” Patients may experience adverse side effects while taking Viberzi including constipation, nausea, and abdominal pain. Xifaxan may cause nausea and an increase in alanine aminotransferase.

Viberzi is manufactured by Patheon Pharmaceuticals Inc, and Xifaxan is marketed by Salix Pharmaceuticals

Nephrogenic Systemic Fibrosis Manifesting a Decade After Exposure to Gadolinium


Importance  Nephrogenic systemic fibrosis (NSF) is a fibrosing skin disorder that develops in patients with kidney failure and has been linked to exposure to gadolinium-containing contrast agents. The time between exposure to gadolinium and the initial presentation of NSF is typically weeks to months but has been documented to be as long as 3½ years. We report a case of NSF developing 10 years after exposure to gadolinium.

Observations  A long-term hemodialysis patient was exposed to gadolinium several times between 1998 and 2004 during magnetic resonance angiography of his abdominal vessels and arteriovenous fistula. In 2014, he was seen at our clinic with new dermal papules and plaques. Biopsy of affected skin showed thickening of collagen, CD34+ spindle cells, and increased mucin in the dermis, supporting the diagnosis of NSF.

Conclusions and Relevance  The clinical history and histopathological features of this case support the diagnosis of NSF 10 years after exposure to gadolinium. Although the use of gadolinium contrast agents in patients with kidney failure has markedly decreased, patients with exposure to gadolinium years to decades previously may manifest the disease.

India’s heat wave: More than 1,000 people have died in record high temperatures.


474375758-indian-girls-walk-home-during-a-hot-summer-day-in
Indian girls walk home during a hot summer day in Allahabad on May 22, 2015. Nationwide, more than 1,000 people have died during the current heat wave.

One of the worst heat waves in recent history is underway in India, with BBC Newsreporting that more than 1,000 people have died in less than a week. The Hindustan Times reports that most of the victims are construction workers, the elderly, or the homeless. Local governments are calling for drinking water camps and public education campaigns with heat safety tips—measures that aren’t likely to help much. In India, most people dying from the heat are likely too poor to afford to take a break from work to cool down.

In the hardest-hit areas, temperatures have been up to 10 degrees Fahrenheit above normal for several days during what is usually the hottest time of the year. In New Delhi, temperatures were so hot—reaching 113 degrees Fahrenheit—they melted the roads. In Hyderabad, 26 of 31 days this month have been or are forecasted to be hotter than normal. According to India’s Meteorological Department, the temperature hit a stunning 117 degrees Fahrenheit on Tuesday at Titlagarh in Odisha—the hottest temperature nationwide, and just 5 degrees below the country’s all-time record.

But at least these places had a “dry heat,” and overnight temperatures have been falling into the 80s. Along the coast, temperatures were slightly lower, but much higher humidity levels created a punishing heat index that persisted throughout the night. In Mumbai, for example, the heat index bottomed out just below 100 degrees Fahrenheit, and only for a few hours overnight Wednesday. In severe heat waves, oppressively hot overnight temperatures are extremely deadly, because there’s just no chance for overheated bodies to cool off.

That means the “misery index”—a creation of Web developer Cameron Beccario that factors in both heat and humidity—is off the charts nearly nationwide.

Next to parts of the Amazon River basin, coastal India typically experiences the highest heat indexes of anywhere on the planet. And global warming is making it worse. A recent study in Nature Climate Change showed that increasing heat stress is already limiting India’s labor capacity—the ability for humans to do work outdoors—with side effects including fainting, disorientation, and seizures. According to a separate study, heat stress will be increasingly deadly in the years to come. Withmore than 250 million farmers, nearly as many as the entire population of the United States, this is a recipe for disaster.

The combination of exceptional heat stress and a still largely rural economy makes India uniquely vulnerable to heat waves. Last year Prime Minister Narendra Modi made universal electricity access by 2019 a key part of his election platform. (Currently a quarter of the country’s 1.25 billion people don’t have electricity.) Air conditioning use in India is growing at a whopping 20 percent per year, putting a huge strain on the country’s still fragile power grid and boosting its greenhouse gas emissions. Electrifying India is a major challenge, and arguably the single most important use of a dwindling global carbon budget. Beyond India, skyrocketing air conditioning demand in poor countries poses tough ethical questions—it’s hard to justify growing greenhouse gas emissions in relatively wealthy parts of the planet when people are literally dying of heat in the tropics.

dcmax6
Temperatures in India this week are approaching all-time records.

NOAA Climate Prediction Center

Conditions like this—horrible heat, and the vast majority of people without access to air conditioning—will continue until the monsoon season arrives in early June. The Indian monsoon is, in my opinion, the most important weather forecast in the world, and the outlook for this year’s rains isn’t great. With so many farmers dependent on the rains­—which produce 70 percent of the year’s total rainfall in just four months—the monsoon is sometimes called “India’s real finance minister.” Though the rains are expected to arrive on time this year, the seasonal total could disappoint for reasons similar to last year’s failure: A growing El Niño and an unfavorable distribution of heat in the Indian Ocean could stifle thunderstorms. Should the monsoon’s northward progression stall out like last year’s, India could have several more weeks of scorching heat to come.